Skip to content
Navigate to homepage - Cerba Research

Roundtable Report – Infectious Disease Clinical Trials: Navigating Innovation & Rising Complexity

COVID-19 accelerated infectious disease R&D, but timelines and funding are now normalizing. Persistent operational barriers remain, and improved surveillance and communication are needed to enhance vaccine development and trial efficiency.

Our roundtable report from the World Vaccine Congress 2024 discusses the evolving landscape for infectious disease clinical trials, the operational barriers for therapeutics and vaccine development, and why improving epidemiologic surveillance and communication are critical to strengthening site and patient enrollment in clinical trials.

Panelists

Nele Langenaken

General Manager, Cerba Research

Chijioke Bennett

Senior Director, Clinical Development, Novavax

Grace Chen

Vaccine Development Consultant

Trina Racine

Director, Vaccine Development, VIDO

John Rex

Chief Medical Officer, F2G

Roxana Rustomjee

Senior Director, Clinical Development, Infectious Diseases, BioNTech

Janelle Hart

Managing Editor, Custom Content, Citeline (Moderator)

Nele Langenaken – General Manager, Cerba Research

Chijioke Bennett – Senior Director, Clinical Development, Novavax

Grace Chen – Vaccine Development Consultant

Trina Racine – Director, Vaccine Development, VIDO

John Rex – Chief Medical Officer, F2G

Roxana Rustomjee – Senior Director, Clinical Development, Infectious Diseases, BioNTech

Janelle Hart – Managing Editor, Custom Content, Citeline (Moderator)

Reach out to our experts and discover how we can help you advance your clinical trial